Crystalline forms of an antiviral benzimidazole compound

Details Crystalline forms of an antiviral benzimidazole compound Crystalline forms of an antiviral benzimidazole compound

2000-10-06

2002-10-22

Fonde, Kathleen Kahler (Department: 1623)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

Reexamination Certificate

active

06469160

ABSTRACT:

This application is a Rule 371 Application of PCT/EP99/02214, filed Apr. 1, 1999, which claims priority to Great Britain Patent Application No. 9807354.7, filed Apr. 7, 1998.
BACKGROUND OF THE INVENTION
The present invention relates to anhydrous crystalline forms and solvates of the antiviral compound 5,6-dichloro-2-(isopropylamino)-1-(&bgr;-L-ribofuranosyl)-1H-benzimidazole (also known as 1263W94; a compound of formula (I)), pharmaceutical formulations comprising anhydrous crystalline forms and solvates of this compound, and their use in therapy.
5,6-Dichloro-2-(isopropylamino)-1-(&bgr;-L-ribofuranosyl)-1H-benzimidazole (1263W94) is a benzimidazole derivative useful in medical therapy. WO96/01833 discloses 5,6-dichloro-2-(isopropylamino)-1-(&bgr;-L-ribofuranosyl)-1H-benzimidazole and its use for the treatment or prophylaxis of viral infections such as those caused by herpes viruses. The compound as disclosed in WO96/01833 is an amorphous, non-crystalline, hygroscopic material.
The structure of 5,6-dichloro-2-(isopropylamino)-1-(&bgr;-L-ribofuranosyl)-1H-benzimidazole, a compound of formula (I) is shown below:
We have now found that the compound of formula (I) may be prepared in novel crystalline forms and solvates. The novel crystalline forms and solvates of the present invention are more thermodynamically stable than the amorphous form disclosed in WO96/01833. The novel crystalline forms and solvates have the further advantage that they are essentially non-hygroscopic. These crystalline forms and solvates have good storage properties and can be readily formulated into pharmaceutical compositions such as tablets, capsules, and liquid systems. The crystalline forms and solvates may be characterized by their X-ray powder diffraction patterns.


REFERENCES:
patent: 3399987 (1968-09-01), Woods et al.
patent: 3555040 (1971-01-01), Frick et al.
patent: 3655901 (1972-04-01), Jensen et al.
patent: 5248672 (1993-09-01), Townsend et al.
patent: 5360795 (1994-11-01), Townsend et al.
patent: 5473063 (1995-12-01), Classon et al.
patent: 5574058 (1996-11-01), Townsend et al.
patent: 5646125 (1997-07-01), Townsend et al.
patent: 5654283 (1997-08-01), Townsend et al.
patent: 5665709 (1997-09-01), Townsend et al.
patent: 6077832 (2000-06-01), Chamberlain et al.
patent: 9207867 (1992-05-01), None
patent: 9408456 (1994-04-01), None
patent: WO96/01833 (1996-01-01), None
patent: 9601833 (1996-01-01), None
patent: WO97/25337 (1997-07-01), None
patent: WO99/51617 (1999-10-01), None
Gordon et al., “Kinetics of Decay in the Expression of Interferon-Dependent mRNAs Responsible for Resistance to Virus,”Proc. National Academy Sciences USA, 77(1), 452-456 (Jan. 1980).*
Devivar et al., “Benzimidazole Ribonucleosides: Observation of An Unexpected Nitration WHen Performing Non-Aqueous Diazotizations with t-butyl Nitrite”,Bioorganic&Medicinal Chemistry Letters, 2(9), 1105-1110 (Sep. 1992).*
Tigges et al., “Human CD8+ Herpes Simplex Virus-Specific Cytotoxic T-Lymphocyte Clones Recognize Diverse Viron Protein Antigens,”Journal of Virology, 66(3), 1622-1634 (Mar. 1992).*
Devivar et al., “Benzimidazole Ribonucleosides: Design, Synthesis and Antiviral Activity of Certain 2-(Alkylthio)-and 2-(benzylthio)-5,6-dichloro-1-(&bgr;-D-ribofuranosyl)benzimidazoles,”Journal of Medicinal Chemistry, 37(18), 2942-2949 (Sep. 2, 1994).*
Townsend et al.(VII), “Design, Synthesis, and Antiviral Activity of Certain 2,5,6-Trihalo-1-(&bgr;-D-ribofuranosyl)benzimidazoles,”Journal of Medicinal Chemistry, 38(20), 4098-4105 (Sep. 25, 1995).*
Yankulov et al., “The Transcriptional Elongation Inhibitor 5,6-Dichloro-1-&bgr;-D-ribofuranosylbenzimidazole Inhibits Translation Factor IIH-Associated Protein Kinase,”Journal of Biological Chemistry, 270(41), 23922-23925 (Oct. 13, 1995).*
Nassiri et al., “Comparison of Benzimidazole Nucleosides and Ganciclovir on the In Vitro Prol;iferation and Colony Formation of Human Bone Marrow Progenitor Cells,”British Journal of Haematology, 93(2), 273-279 (May, 1996).*
Gudmundsson et al., “Synthesis and Antiviral Activity of Certain 5'-Modified Analogs of 2,5,6-Trichloro-1-(&bgr;-D-ribofuranosyl)benzimidazole,”Journal of Medicinal Chemistry, 40(5), 785-793 (Feb. 28, 1997).*
Zou et al., “Design, Synthesis, and Antiviral Evaluation of 2-Chloro-5,6-dihalo-1-(&bgr;-D-ribofuranosyl)benzimidazoles as Potential Agents for Human Cytomegalovirus Infections,”Journal of Medicinal Chemistry, 40(5), 811-818 (Feb. 28, 1997).*
Fessenden et al.,Ch. entitled “Crystallization,”Organic Laboratory Techniques, 3rd Edition, Brooks/Cole (Canada), 2001, only preface and pp. 23-38 supplied. ††.*
Fieser, Louis D., Ch. 7 inOrganic Experiments, D. C. Heath and Company, Boston, MA, 1964, only preface and pp. 41-51 supplied. †\.*
A. Graul, et al., “1263W94 Antiviral”,Drugs of the Future, vol. 22, No. 7, pp. 707-710 (1997).

Affiliated with

Also associated with

Rating

Crystalline forms of an antiviral benzimidazole compound does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline forms of an antiviral benzimidazole compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline forms of an antiviral benzimidazole compound will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2949729